Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for Hard-to-Treat lung cancer

NCT ID NCT04042558

Completed Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progressed after targeted therapy. The main goal was to see how many patients' tumors shrank or disappeared after four cycles of treatment. The study also tracked how long patients lived without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Carboplatin, Pemetrexed, Atezolizumab, and Bevacizumab (a combination of chemotherapy and immunotherapy drugs)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose targeted therapies have stopped working.
What could go wrong
This is a phase 2 trial, so it is still early. The combination may cause significant side effects, and not all patients may benefit. Results need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK GENE REARRANGEMENT POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK GENE REARRANGEMENT POSITIVE EGFR GENE MUTATION NSCLC STAGE IIIB NSCLC STAGE IV ROS1 GENE MUTATION

Contacts and locations

Locations

  • CHD Vendée La Roche sur Yon

    La Roche-sur-Yon, France

  • CHIC

    Créteil, France

  • CHR Orléans

    Orléans, France

  • CHU

    Angers, France

  • CHU

    Grenoble, France

  • CHU

    Lille, France

  • CHU

    Pierre-Bénite, France

  • CHU

    Rennes, France

  • CHU

    Rouen, France

  • CHU

    Toulouse, France

  • CHU Gabriel MONTPIED

    Clermont-Ferrand, France

  • CHU Limoges

    Limoges, France

  • CHU Lyon Louis Pradel

    Bron, France

  • CHU Lyon, Croix-Rousse,

    Lyon, France

  • CHU Réunion St Denis

    La Réunion, France

  • CHU Réunion St Pierre

    La Réunion, France

  • CHU-Hôpital MORVAN

    Brest, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Hospitalier

    Annecy, France

  • Centre Hospitalier

    Villefranche, France

  • Centre Hospitalier Bretagne Atlantique

    Vannes, France

  • Centre Léon Bérard

    Lyon, France

  • Centre Paul Strauss

    Strasbourg, France

  • HIA Percy

    Percy, France

  • HIA R.Picqué

    Villenave-d'Ornon, France

  • HIA St Anne

    Toulon, France

  • Hopital Foch

    Paris, France

  • Hôpital Haut Lévêque,Centre François Magendie

    Pessac, France

  • Hôpital Nord

    Marseille, France

  • ICLN, St Priez en Jarez

    Saint-Priest-en-Jarez, France

  • institut Curie

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.